129901 20241125101147.0 doi 10.3390/md21090478 sideral 136213 ART-2023-136213 eng Graikini, Dimitra Universidad de Zaragoza Bioactivity of fucoidan-rich extracts from fucus vesiculosus against rotavirus and foodborne pathogens 2023 Access copy available to the general public Unrestricted Marine algae are sources of bioactive components with defensive properties of great value against microbial infections. This study investigated the bioactivity of extracts from brown algae Fucus vesiculosus against rotavirus, the worldwide leading cause of acute gastroenteritis in infants and young children. Moreover, one of the extracts was tested against four foodborne bacteria: Campylobacter jejuni, Escherichia coli, Salmonella Typhimurium, and Listeria monocytogenes, and the non-pathogenic: E. coli K12. In vitro tests using MA104 cells revealed that both whole algae extracts and crude fucoidan precipitates neutralized rotavirus in a dose-responsive manner. The maximum neutralization activity was observed when the rotavirus was incubated with 100 μg mL−1 of the hydrochloric acid-obtained crude fucoidan (91.8%), although crude fucoidan extracted using citric acid also demonstrated high values (89.5%) at the same concentration. Furthermore, molecular weight fractionation of extracts decreased their antirotaviral activity and high molecular weight fractions exhibited higher activity compared to those of lower molecular weight. A seaweed extract with high antirotaviral activity was also found to inhibit the growth of C. jejuni, S. Typhimurium, and L. monocytogenes at a concentration of 0.2 mg mL−1. Overall, this study expands the current knowledge regarding the antimicrobial mechanisms of action of extracts from F. vesiculosus. info:eu-repo/grantAgreement/ES/DGA/A20-23R info:eu-repo/grantAgreement/EC/H2020/801586/EU/International Doctoral Programme for Talent Attraction to the Campus of International Excellence of the Ebro Valley/IberusTalent This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 801586-IberusTalent info:eu-repo/grantAgreement/ES/MINECO/AGL2017-82987-R info:eu-repo/semantics/openAccess by http://creativecommons.org/licenses/by/3.0/es/ 4.9 2023 PHARMACOLOGY & PHARMACY 46 / 354 = 0.13 2023 Q1 T1 CHEMISTRY, MEDICINAL 14 / 72 = 0.194 2023 Q1 T1 0.88 2023 Drug Discovery 2023 Q1 Pharmacology, Toxicology and Pharmaceutics (miscellaneous) 2023 Q1 Pharmaceutical Science 2023 Q1 9.6 2023 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Soro, Arturo B. Sivagnanam, Saravana P. Tiwari, Brijesh K. Sánchez, Lourdes Universidad de Zaragoza (orcid)0000-0001-5964-823X 2008 780 Universidad de Zaragoza Dpto. Produc.Animal Cienc.Ali. Área Tecnología de Alimentos 21, 9 (2023), 478 [16 pp.] Mar. drugs Marine Drugs 1660-3397 834441 http://zaguan.unizar.es/record/129901/files/texto_completo.pdf Versión publicada 2648877 http://zaguan.unizar.es/record/129901/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:129901 articulos driver 2024-11-22-12:05:02 ARTICLE